Medical Injectable Drug Delivery Systems sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Medical Injectable Drug Delivery Systems
1.1 - About Medical Injectable Drug Delivery Systems sector
Companies in the Medical Injectable Drug Delivery Systems category design and manufacture devices that enable safe, accurate, and convenient administration of injectable therapies across clinical and home settings. They support small molecules and complex biologics with solutions that improve dosing precision, user ergonomics, and sharps safety, while integrating drug–device combination expertise to help customers bring self-injection and infusion products to market efficiently and at scale.
Offerings commonly include safety and prefilled syringe platforms featuring integrated needle shields and tamper-evident components. Vendors develop single- and multi-use autoinjectors and reusable or disposable pen injectors optimized for self-administration, alongside on-body wearable injectors for large-volume biologics. Some provide needle-free jet systems and ambulatory infusion pumps, plus combination-product engineering, human factors validation, connected dose tracking, and sterile manufacturing that aligns with ISO 13485 and global regulatory requirements.
Primary customers are biopharma developers, hospital and infusion centers, and home healthcare and specialty pharmacy providers. Outcomes include faster time-to-market for drug–device combinations, improved patient adherence and experience in self-administration, reduced needlestick injuries and dosing errors, and stronger regulatory compliance with validated human factors and quality systems. These companies also help lower total cost of care by enabling efficient delivery of complex injectable therapies.
2. Buyers in the Medical Injectable Drug Delivery Systems sector
2.1 Top strategic acquirers of Medical Injectable Drug Delivery Systems companies
TriSalus
- Description: Provider of a therapeutic platform that combines innovative Pressure-Enabled Drug Delivery technology with standard-of-care therapies and an investigational immunotherapy to overcome intratumoral pressure and immunosuppression, aiming to improve treatment outcomes for patients with liver and pancreatic solid tumors.
- Key Products:
- Pressure-Enabled Drug Delivery (PEDD) Method: Utilizes controlled pressure to enhance intratumoral drug penetration, enabling systemic immunotherapies to reach liver and pancreatic tumors more effectively
- Integrated Therapeutic Platform: Combines PEDD with immune-reactivating therapies to simultaneously overcome immunosuppression and delivery barriers specific to liver and pancreatic cancers
- Investigational Immunotherapy: Proprietary immune-modulating agent designed to work synergistically with PEDD and standard treatments to reactivate immune cells within solid tumors
- Organ-Targeted Delivery Approach: Tailors drug delivery parameters to specific organ and disease biology, optimizing therapeutic concentration while minimizing systemic exposure.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Medical Injectable Drug Delivery Systems sector
M&A buyer group 1: Drug Delivery
Acorda
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biotechnology therapies aimed at restoring neurological function for people with nervous system disorders. The company researches, develops and commercializes treatments for multiple sclerosis, spinal cord injury, stroke, epilepsy and is advancing a therapeutic approach for chronic heart failure, collaborating with patient, medical and scientific communities to deliver innovative medicines.
- Key Products:
- Ampyra®: Oral sustained-release formulation of 4-aminopyridine that blocks potassium channels to improve walking ability in multiple-sclerosis patients, providing symptomatic neurological improvement
- Parkinson’s disease therapy program: R&D effort creating drug candidates that aim to restore neurological function and relieve motor symptoms in Parkinson’s through proprietary small-molecule approaches
- Migraine therapy program: Development of pharmacological treatments designed to reduce migraine frequency and severity by targeting neuronal signaling pathways related to neurological dysfunction
- Sustained-release 4-aminopyridine technology: Drug-delivery platform covered by patents enabling controlled release of 4-aminopyridine to maintain therapeutic plasma levels for extended neurological benefit.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Medical Injectable Drug Delivery Systems sector
3.1 - Buyout funds in the Medical Injectable Drug Delivery Systems sector
2.2 - Strategic buyer groups for Medical Injectable Drug Delivery Systems sector
4 - Top valuation comps for Medical Injectable Drug Delivery Systems companies
4.2 - Public trading comparable groups for Medical Injectable Drug Delivery Systems sector
Valuation benchmark group 1: Injectable Drug Delivery Manufacturers
Stevanato Group
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of integrated systems, processes, and services for the pharmaceutical and healthcare industries, specializing in glass primary packaging, drug delivery devices, and assembly and packaging equipment. Offers comprehensive solutions to ensure the integrity and safety of medications through advanced technologies and engineering excellence.
- Key Products:
- Precision Glass Forming: Advanced glass forming lines for pharmaceutical packaging
- Vision Inspection Systems: Equipment for inspecting drug containment solutions
- Drug Delivery Devices: Production of autoinjectors, pen injectors, and wearable injectors
- Assembly and Packaging: Solutions for efficient assembly and packaging of medical products
- Pre-Sterilized Containers: EZ-fill® technology for ready-to-use drug packaging solutions.